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Abstract
In recent decades, astrocytes have emerged as key pieces in the maintenance of normal functioning of the central nervous
system. Any impairment in astroglial function can ultimately lead to generalized disturbance in the brain, thus
pharmacological targets associated with prevention of astrocyte death are actually promising. Subtype 3 of metabotropic
glutamate receptors (mGluR3) is present in astrocytes, its activation exerting neuroprotective roles. In fact, we have
previously demonstrated that mGluR3 selective agonists prevent nitric oxide (NO)-induced astrocyte death. However,
mechanisms responsible for that cytoprotective property are still subject to study. Although inhibition of adenylyl cyclase
by mGluR3 activation was extensively reported, the involvement of reduced cAMP levels in the effects of mGluR3 agonists
and the association between cAMP decrease and the downstream pathways activated by mGluR3 remain neglected. Thus,
we studied intracellular signaling mediating anti-apoptotic actions of mGluR3 in cultured rat astrocytes exposed to NO. In
the present work, we showed that the cytoprotective effect of mGluR3 agonists (LY379268 and LY404039) requires both the
reduction of intracellular cAMP levels and activation of Akt, as assessed by MTT and TUNEL techniques. Moreover, dibutyryl-
cAMP impairs Akt phosphorylation induced by LY404039, indicating a relationship between mGluR3-reduced cAMP levels
and PI3K/Akt pathway activation. We also demonstrated, by co-immunoprecipitation followed by western-blot, that the
mGluR3 agonists not only induce per se survival-linked interaction between members of the NF-kB family p65 and c-Rel, but
also impede reduction of levels of p65-c-Rel dimers caused by NO, suggesting a possible anti-apoptotic role for p65-c-Rel.
All together, these data suggest that mGluR3 agonists may regulate cAMP/Akt/p65-c-Rel pathway, which would contribute
to the protective effect of mGluR3 against NO challenge in astrocytes. Our results widen the knowledge about mechanisms
of action of mGluR3, potential targets for the treatment of neurodegenerative disorders where a pathophysiological role for
NO has been established.
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Introduction
Normal function of the central nervous system (CNS) depends
on adequate maintenance of the neuronal microenvironment.
This requires, in turn, the presence and correct functioning of
astrocytes, which regulate extracellular ionic composition, remove
neurotransmitter excess at the synaptic cleft and contribute to
functional hyperemia in active brain tissue, among several other
essential functions [1]. Therefore, loss of astroglia or impairment
in astroglial function can lead to generalized disturbance in the
brain. We have demonstrated that the inflammatory stimulus of
bacterial lipopolysaccharide (LPS)+interferon-c (IFN-c) induces
astroglial death, which is mediated by nitric oxide (NO)
production [2,3]. Moreover, an NO donor, DETA/NO, also
induces astrocyte death [3].
Metabotropic glutamate receptors (mGluR) belong to the family
of G-protein coupled receptors. Eight mGluR subtypes have been
cloned and are classified into groups I (mGluR1 and 5), II
(mGluR2 and 3) and III (mGluR4, 6, 7 and 8). Groups II and III
are negatively coupled to adenylyl cyclase, thereby inhibiting
cyclic AMP (cAMP) formation [4]. Several reports show mGluR
expression in glial cells. Of group II mGluRs, only the mGluR3
subtype was found in astrocytes [5] where it may have a protective
role. In fact, agonists of group II mGluR are more effective against
excitotoxic death in mixed neuron-glia cultures than in pure
neuronal cultures [6]. Activation of group II mGluR stimulates
release of neuroprotective factors such as brain derived neuro-
trophic factor and transforming growth factor-b (TGF-b) from
astrocytes [7]. Moreover, a synthetic mGluR3 agonist, (2) 2-oxa-
4-aminocyclo-[3.1.0] hexane-4,6-dicarboxylic acid (LY379268),
protects cultured astrocytes against apoptotic death induced by
oxygen/glucose deprivation [8]. Concordantly, our previous
results demonstrated that mGluR3 activation by LY379268
prevents DETA/NO-induced cell death in primary astrocytes by
a mechanism involving p53, Bax and Bcl-2 modulation and
prevention of mitochondrial membrane permeabilization [3].
For the present study, we decided to investigate pathways
activated by mGluR3 which might mediate the protective actions
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because its members are linked to induction of nitric oxide
synthase (NOS) transcription but also because it was recently
postulated that, depending on the composition of the dimers
activated, they may have pro- or anti-apoptotic effects. It is now
proposed that p65-p50 heterodimers may lead to apoptosis,
whereas c-Rel containing dimers have a protective role [9]. We
also studied the PI3K/Akt pathway, which has frequently been
associated with mGluR3 activity [10] and has a major role in the
induction of survival signals [11,12]. Finally, we analyzed whether
mGluR3-induced inhibition of cAMP production is involved in the
anti-apoptotic action of this receptor subtype in astrocytes.
Our results demonstrate that mGluR3-induced cAMP reduc-
tion, Akt activation and p65-c-Rel interaction mediate the anti-
apoptotic effect of mGluR3 agonists in NO-challenged astrocytes,
possibly as part of a unique cAMP/Akt/p65-c-Rel signaling
pathway.
Materials and Methods
Ethics Statement
All experimental procedures were approved by the Committee
on Ethics of the School of Medicine (University of Buenos Aires,
Resolution No 1889/06) and were carried out in compliance with
the guidelines of the NIH Guide for the Care and Use of
Laboratory Animals.
Materials
The (2)2-oxa-4-aminobicyclo[3.1.0]hexane-4,6-dicarboxylic
acid (LY379268) was purchased from TOCRIS Bioscience (MO,
USA).
The (2)-(1R,4S,5S,6S)-4-amino-sulfonylbicyclo[3.1.0]-hexane-
4,6-dicarboxylic acid (LY404039) was custom-synthesized by
Selleck Chemicals (ShangHai, China). Interferon-c (IFN-c) was
purchased from Boehringer Ingelheim (Buenos Aires, Argentina).
Diethylenetriamine nitric oxide adduct (DETA/NO), LPS (Esch-
erichia coli, serotype O127:B8), dibutyryl-cAMP, 8-Br-cGMP, Akt
inhibitor and anti-b-actin antibody were purchased from Sigma-
Aldrich Corporation (MO, USA). Fetal bovine serum (FBS) was
obtained from PAA laboratories GmBH (Pasching, Austria).
DMEM/F-12, antibiotic and antimycotic were purchased from
Invitrogen Life technologies (CA, USA). Anti-c-Rel and anti-
histone antibodies and protein A/G agarose were purchased from
Santa Cruz Biotechnology (CA, USA). Anti-p65 antibody was
purchased from BD Biosciences (CA, USA). Anti-GFAP, anti-
mGluR2/3, biotinylated donkey anti-mouse and anti-rabbit
antibodies were obtained from Chemicon International Inc.
(CA, USA). Anti-phospho-Akt, anti-Akt and anti-IkBa antibodies
were obtained from Cell Signalling Technology Inc. (MA, USA).
TUNEL reagents were obtained from Roche Diagnostics
(Mannheim, Germany).
Astrocyte primary cultures
Cerebral hemispheres of 1- to 2-day-old postnatal Wistar rat
pups were dissected, freed from meninges and cut into small
fragments. Tissue was disrupted by triturating it through a needle
in DMEM/F-12 medium containing 10% FBS, 50 mg/mL
streptomycin, 0.125 mg/mL amphotericin, and 50 U penicillin.
Then cells were seeded in 75 cm
2 poly-L-lysine coated culture
flasks. Cultured cells were kept at 37uCi n5 %C O 2. After reaching
confluence, astrocytes were separated from microglia and
oligodendrocytes by shaking flasks for 24 h in an orbital shaker
at 240 rpm. Cells were tripsinized, subcultured and, after 2–3 days
of stabilization, incubated with the drugs in MEM containing 2%
FBS, 2 mM L-glutamine, 50 mg/mL streptomycin, 0.125 mg/mL
amphotericin and 50 U penicillin.
Cultures were routinely more than 95% pure astrocytes when
assessed by glial fibrillary acidic protein (GFAP) immunostaining
as previously described [2].
Treatments
Astrocytes were incubated with 1 mg/mL LPS and 50 ng/mL
IFN-c in the presence or absence of LY379268 for 30 min, or with
1 mM DETA/NO in the presence or absence of 100 mM
LY379268 or LY404039 (highly selective group II mGluR
agonists) and Akt inhibitor (0.5 mM), PI3K/Akt inhibitor
(20 mM), db-cAMP (1 mM) or 8Br-cGMP (1 mM) for 30 min or
48 h. When treated with Akt or PI3K/Akt inhibitors, astrocytes
were preincubated with the inhibitor alone for 60 min and then
treated with the other drugs. Control cells were grown in MEM
containing 2% FBS, 2 mM L-glutamine, 50 mg/mL streptomycin,
0.125 mg/mL amphotericin, and 50 U penicillin.
Double immunocytochemistry for mGluR2/3 and GFAP
2610
4 astrocytes were seeded on poly-L-lysinated coverslips in
culture medium for 96 h and fixed with 4% formaldehyde in PBS
(140 mM NaCl, 10 mM NaH2PO4/Na2HPO4, pH 7.4) for
30 min at 4uC. Cells were permeabilized by microwave irradiation
in citrate buffer (10 mM, pH 6.0) and blocked with 10% donkey
serum and 0.2 mL/mL avidin blocking solution in PBS for 1 h at
room temperature (RT). Primary antibodies (anti-mGluR2/3
1:100 and anti-GFAP 1:200) were incubated in buffer containing
1% donkey serum and 0.2 mL/mL biotin blocking solution in
PBS overnight at 4uC. Then, cells were incubated with secondary
antibodies (biotinilated donkey-anti-rabbit IgG 1:400 and TRITC-
conjugated anti-mouse IgG 1:150) for 1 h at RT, followed by
FITC-conjugated avidin 1:600 (Vector Laboratories) in 10 mM
Hepes pH 7.9, for 20 min at RT. Coverslips were mounted with
49,6-diamino-2-phenylindole (DAPI, Vectashield, Vector Labora-
tories Inc., CA, USA) and astrocytes were visualized in a
fluorescence microscope (Zeiss Axiophot, Germany). Negative
control slides were incubated in dilution buffer instead of primary
antibody.
Metabolic activity assay
Metabolic activity of viable cells was measured by the 3-[4,5-
dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) as-
say. Briefly, cells (4610
4) were washed and incubated for 4 h in
100 mL Krebs buffer plus 50 mg of MTT reagent dissolved in
10 mL phosphate buffered saline (PBS) at 37uC. Formazan crystals
obtained from MTT reduction were dissolved in 100 mL 0.04 M
HCl in isopropanol and optical density (OD) was measured in a
microplate spectrophotometer at 595 nm.
Microscopic determination of DNA fragmentation by
terminal deoxynucleotidyl transferase-mediated dUTP
nick end labeling (TUNEL) assay
Cells were fixed with 4% formaldehyde in PBS pH 7.4 for
30 minutes and permeabilized by microwave irradiation. DNA
strand breaks were labeled with digoxigenin-deoxy-UTP using
terminal deoxynucleotidyl transferase (TdT, 0.18 U/mL) as
previously described [13]. The incorporation of nucleotides into
the 39-OH end of damaged DNA was detected with an anti-
digoxigenin-fluorescein antibody. Slides were mounted with
mounting medium for fluorescence containing DAPI for DNA
staining and visualized in a fluorescence microscope (Axiophot,
Cell Signals Activated by mGluR3
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incubated in absence of TdT.
Total protein extracts
1610
6 astrocytes per well were scrapped into PBS+10 mM
NaF+1m MN a 3VO4 and centrifuged at 2000 rpm. Pellets were
homogenized in lysis buffer (50 mM Tris-HCl pH 7.4, 1 mM
EDTA, 150 mM NaCl, 1% NP-40) containing protease and
phosphatase inhibitors (1 mM PMSF, 1 mg/mL aprotinin, 1 mg/
mL leupeptin, 1 mg/mL pepstatin A, 10 mM NaF, 1 mM
Na3VO4). Following sonication and centrifugation at 12000 rpm
for 30 min, the supernatant was assayed by immunoblot. Protein
concentration in samples was determined by the Bradford method
(BioRad Laboratories, CA, USA) using bovine serum albumin as
standard.
Nuclear and cytosolic extracts
4–5610
6 astrocytes were grown in Petri dishes and treated with
corresponding drugs for 30 min. Cells were scrapped into PBS-
PMSF (1 mM), centrifuged at 2500 rpm and resuspended in
150 mL lysis buffer A (10 mM Hepes, 10 mM KCl, 2 mM MgCl2,
500 mM DTT, 1 mM PMSF, 5 mg/mL aprotinin, 5 mg/mL
leupeptin, 5 mg/mL pepstatin A, 500 mMN a 3VO4, 1 mM NaF),
followed by incubation with 1% NP-40. Homogenates were
centrifuged at 14000 rpm for 15 min and supernatants collected as
the cytosolic fraction. Pellets were resuspended in buffer B (20 mM
Hepes, 25% glycerol, 420 mM NaCl, 1.5 mM MgCl2, 200 mM
EDTA, 500 mM DTT, plus protease and phosphatase inhibitors)
and shaken on ice for 30 min. After centrifugation at 14000 rpm
for 15 min, supernatants (nuclear extracts) were diluted in buffer C
(20 mM Hepes, 20% glycerol, 50 mM KCl, 200 mM EDTA,
500 mM DTT, 1 mM PMSF). Protein concentration was deter-
mined by the Bradford method. As a control of subcellular
fractioning, we ran immunoblots of nuclear and cytosolic extracts
using anti-histone antibody, detecting a positive band only in the
nuclear fraction.
Western blots
30–50 mg of proteins were size-fractionated in 8% (or 15% for
IkBa) sodium dodecyl sulfate (SDS)-polyacrilamide gel, then
electrotransferred to a polyvinylidene difluoride membrane. Blots
were blocked for 1–2 h in 5% nonfat dry milk-TBS-0.1% Tween
20 and incubated overnight at 4uC with appropriate primary
antibodies in 5% milk-TBS-0.1% Tween 20 (anti-p65 1:400, anti-
c-Rel 1:5000, anti-IkBa 1:1000) or in 5% BSA- TBS-0.1% Tween
20 (anti-Akt 1:2000, anti-phospho-Akt 1:1000). This was followed
by 1 h incubation with the respective biotinylated secondary
antibody and 1 h incubation with Streptavidin-peroxidase (Che-
micon International Inc., CA, USA). Immunoreactivity was
detected by enhanced chemiluminescence (ECL plus, Amersham
Biosciences, GE Healthcare). Bands were analyzed using SCION
Image software. Results were normalized to the internal control b-
actin, except for phospho-Akt, which was expressed as phospho-
Akt/Akt ratio. Values were expressed relative to respective
controls.
Co-immunoprecipitation from nuclear extracts
50–70 mg of nuclear proteins were diluted up to 500 mL in lysis
buffer (50 mM Tris-HCl, 140 mM NaCl, 0.1% NP-40, 1 mM
PMSF, 50 mg/mL aprotinin, 2.3 mg/mL leupeptin, 0.5 mg/mL
pepstatin A, 0.5 mM Na3VO4 and 1 mM NaF). We pre-cleared
with protein A/G agarose to reduce non-specific adsorption. After
centrifuging at 2500 rpm for 10 min at 4uC, supernatants were
incubated with 1 mg of anti-c-Rel antibody overnight at 4uC with
continuous shaking. 20 mL of protein A/G agarose were added
and antigen-antibody complexes precipitated by centrifugation at
2500 rpm for 10 min. Pellets were washed 3 times with washing
buffer (50 mM Tris-HCl pH 7.5, 250 mM NaCl, 0.1% NP-40,
with protease and phosphatase inhibitors) and the final pellet was
resuspended in 25 mL of sample buffer 1X, then loaded onto a
SDS-PAGE to run immunoblots for p65. As a control of specificity
of immunoprecipitation, nuclear proteins were precipitated with
an irrelevant IgG of the same origin as anti-c-Rel (anti-mGluR2/
3). As a control of the presence of p65 in nuclear extracts, non-
immunoprecipitated extracts were used in western-blots for p65
(input).
Statistical analysis
Data were expressed as mean 6 SEM and analyzed by one
sample Student’s t test, unpaired Student’s t test, or one-way
analysis of variance (ANOVA) followed by Dunnet or Bonferroni
Multiple Comparisons Test, when corresponding. For multiple
Student’s t tests we used the Holm adjustment of the significance
level. For other statistical tests than the Holm adjustment, the
significance level was p,0,05.
Results
Presence of mGluR3 in astrocytes cultures
As previously described [3,14–19] we confirmed the expression
of group II mGluRs in rat astrocytes by immunocytochemistry
(Fig. 1). Despite the limited availability of selective antibodies for
mGluR2 or mGluR3, we postulate that staining obtained with
mGluR2/3 antibody corresponds to mGluR3, since only this
subtype has been found in astrocytes [20,21].
Signaling pathways mediating mGluR3 actions
Once we had demonstrated that astrocytic mGluR3 activation
prevents NO-induced astrocyte death and reduces LPS/IFN-c-
stimulated NO synthesis [3], we were interested in elucidating the
signaling pathways involved in mGluR3-induced cytoprotection.
For this purpose, we used two mGluR3 agonists with similar
pharmacological properties: LY379268 and LY404039 [22,23].
NF-kB family
Since NF-kB family proteins are intimately associated with
iNOS transcription, we analyzed protein expression of several
members of this family. As an approach to their transcriptional
activity, p65 and c-Rel levels were determined from nuclear
extracts, whereas inhibitor IkB levels were determined from
cytosolic extracts.
Cultured astrocytes were incubated with LPS/IFN-c (1 mg/
mL/50 ng/mL) in the presence or absence of a selective mGluR3
agonist LY379268 (100 mM) for 30 min. Mentioned concentra-
tions of LPS/IFN-c and mGluR3 agonist were used all over the
experiments. Treatment with LPS/IFN-c significantly increased
nuclear expression of p65, whereas LY379268 had no effect on
p65 expression either per se or in combination with LPS/IFN-c
(Fig. 2A). However, the agonist did block the inhibitory effect of
LPS/IFN-c on cytosolic IkB levels and simultaneously induced
IkB expression per se (Fig. 2B). Conversely, neither LPS/IFN-c nor
LY379268 significantly modified c-Rel protein levels (Fig. 2C).
A crucial characteristic of NF-kB members is their ability to
form homo- and heterodimers. Some authors recently associated
p65-p50 dimers with neurodegenerative events and c-Rel-
containing dimers with transcription of anti-apoptotic genes
[9,24,25]. Therefore, we also examined the effect of mGluR3
Cell Signals Activated by mGluR3
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followed by western-blot. Both LPS/IFN-c and LY379268 by
themselves significantly increased nuclear levels of p65-c-Rel
complexes, although they showed no additive effect when
combined (Fig. 3B).
We also determined p65-c-Rel interaction after incubation with
pro-apoptotic stimulus DETA/NO (1 mM) for 30 min. It is
known that mM amounts of DETA/NO replicate macrophage
and reactive astrocyte-generated NO [26], which reachs mM
levels. Likewise, our previous data indicate that astrocytes exposed
to LPS/IFN-c release 10-20 mM NO, as measured by Griess
Method. Thus, 1 mM DETA/NO is a good approach to mimic
NO concentrations released by reactive astrocytes in vitro and it
was employed throughout the rest of the experiments. In this case,
DETA/NO inhibited p65-c-Rel dimerization, whereas another
selective mGluR3 agonist, LY404039 (100 mM), restored levels of
the complexes (Fig. 4), suggesting a possible protective role of these
heterodimers in NO-exposed astrocytes. Like LY379268,
LY404039 also induced p65-c-Rel interaction on its own (Fig. 4).
Involvement of cAMP and cGMP in the effects of mGluR3
activation
Since the most direct action triggered by mGluR3 activation is
inhibition of adenylate cyclase and a concomitant reduction in
cAMP intracellular levels, we studied the participation of cAMP in
protective effects of mGluR3 agonists. Cell viability was measured
in astrocytes treated with DETA/NO6LY379268 in the presence
or absence of a non-hydrolyzable analog of cAMP, dibutyryl-
cAMP (1 mM db-cAMP) for 48 h. As we reported previously [3],
DETA/NO significantly reduced astrocyte viability and
LY379268 avoided this effect (Fig. 5). Incubation with db-cAMP
blocked action of LY379268 on cell viability (Fig. 5), indicating
that cAMP has a negative effect on the protection exerted by
mGluR3 activity in astrocytes.
As suggested by Wroblewska et al. (2006), cGMP (the main
second messenger of NO) could be modulated by mGluR3 [27].
We had previously measured cGMP intracellular levels and found
that LY379268 did not modify NO-stimulated cGMP levels [3].
Here, we confirmed these results by incubating astrocytes with a
non-hydrolyzable analog of cGMP, 8-Br-cGMP (1 mM). This
reagent did not alter the protective effect of LY379268 on cell
viability reduced by NO (Fig. 5).
Neither db-cAMP nor 8-Br-cGMP affects astrocyte viability per
se (Fig. 5).
The Akt pathway
Several reports now propose the PI3K/Akt system as an
intracellular target of mGluR3, even in astrocytes [8,10].
Therefore, we analyzed involvement of this pathway in our
experimental model. Astrocytes were incubated with DETA/
NO6LY404039 in the presence or absence of an Akt inhibitor for
48 h and cell viability was assayed. The concentration of the Akt
inhibitor used was 0.5 mM, which showed no activity per se on cell
viability in a dose-response curve (Fig. 6A) and inhibited Akt1 and
2 isoforms, according to previous data [28].
The Akt inhibitor blocked the cytoprotective effect of LY404039
on astrocyte viability reduced by NO (Fig. 6B), indicating that this
pathway mediates anti-apoptotic actions of mGluR3 agonists.
The results for db-cAMP and the Akt inhibitor were reproduced
by the TUNEL technique, in which both reagents were able to
impede the anti-apoptotic effect of the mGluR3 agonist (Table 1).
To further support these results, we also assayed protein levels of
phosphorylated-Akt (phospho-Akt) by western-blot. As a positive
control of the technique, astrocytes were incubated with LPS/
IFN-c [29], which incremented the phospho-Akt/Akt ratio by
100% (Fig. 7A). LY404039 also induced Akt phosphorylation per se
(Fig. 7A and B). As a negative control, astrocytes were co-
incubated with LY404039+the PI3K/Akt pathway inhibitor,
LY294002 (20 mM), which completely blocked Akt phosphoryla-
tion induced by the mGluR3 agonist (Fig. 7A).
We show that the NO donor significantly diminished the
phospho-Akt/Akt ratio, whereas LY404039 prevented this effect
(Fig. 7B), which concords with an anti-apoptotic role for phospho-
Akt.
Interestingly, co-incubation with 1 mM db-cAMP blocked
LY404039-induced Akt phosphorylation (Fig. 7B), suggesting that
this second messenger exerts an inhibitory effect on the mGluR3-
activated PI3K/Akt pathway.
Discussion
Our present results show that three cell signaling mechanisms
are involved in the anti-apoptotic actions of mGluR3 in NO-
exposed rat astrocytes: i) reduction in cAMP levels as a
Figure 1. mGluR3 expression in astrocytes. Immunolabeling for mGluR2/3 (green), GFAP (red) and DAPI (blue) done on rat primary astrocytes.
(A) Immunolabeling for mGluR2/3. Picture B shows mGluR2/3 and GFAP merged images (yellow).
doi:10.1371/journal.pone.0022235.g001
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proteins; ii) the PI3K/Akt pathway, which involves Akt phos-
phorylation and, in turn, a phosphorylating cascade that results in
triggering of survival signals; iii) dimerization between p65 and c-
Rel, transcription factors belonging to the NF-kB family, which
can mediate the transcription of anti-apoptotic genes.
Activation of NF-kB proteins is a ubiquitous event in
inflammatory processes that induces the expression of pleiotropic
genes, from pro-inflammatory genes such as iNOS to anti-
apoptotic genes such as Bcl-2. LPS/IFN-c is known to induce NF-
kB activity [29] leading to up-regulation of iNOS, tumor necrosis
factor-a and cyclooxygenase-2 expression. Here, we found no
effect of LY379268 on LPS/IFN-c-induced p65 expression.
Therefore, inhibition of LPS/IFN-c-induced iNOS expression
by LY379268 that we reported earlier [3] cannot be explained by
any effect of the agonist on p65 nuclear levels. This suggests that
other mechanisms must be involved in regulation of iNOS
expression by mGluR3. Kozuka et al. (2007) observed NF-kB-
independent iNOS induction [30] and Murphy et al. (1995)
reported that mGluR activation inhibits cytokine-induced iNOS
Figure 2. Expression of NF-kB family proteins. Astrocyte primary
cultures were exposed to LPS/IFN-c (1 mg/mL/50 ng/mL)6100 mM
LY379268 for 30 min and nuclear and cytosolic proteic extracts were
used for western-blots of p65 (A), IkBa (B) and c-Rel (C). Values of OD
from bands were normalized to the internal control b-actin and data
expressed relative to control group. Bars represent the mean 6 SEM of
5–6 (A and B) or 3 (C) independent experiments. *p,0.05, **p,0.01,
***p,0.001 versus control. (D) The purity of nuclear and cytosolic
fractions was assayed by western-blot for nuclear histone.
doi:10.1371/journal.pone.0022235.g002
Figure 3. Both LPS/IFN-c and LY379268 induce p65-c-Rel
dimerization. Astrocytes were incubated with LPS/IFN-c (1 mg/mL/
50 ng/mL)6100 mM LY379268 for 30 min. Interaction between p65 and
c-Rel proteins was analyzed from 70 mg of proteic nuclear extracts by
co-immunoprecipitation (IP) with anti-c-Rel antibody followed by
western-blot (WB) for p65. (A) Specificity of the assay was analyzed
by immunoprecipitating nuclear proteins with anti-c-Rel antibody (lane
1) or with an irrelevant IgG of the same origin as the anti-c-Rel antibody
(lane 2), which was not able to precipitate c-Rel-linked p65. (B) Levels of
anti-c-Rel-immunoprecipitated p65 were expressed relative to control
group. Bars represent the mean 6 SEM of 3 independent experiments.
*p,0.05, **p,0.01 versus control. Input corresponds to total content of
p65 in nuclear extracts.
doi:10.1371/journal.pone.0022235.g003
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nucleus [31].
On the other hand, LPS/IFN-c-induced IkBa inhibition was
prevented by LY379268 and this agonist incremented IkBa
expression per se. The evident uncoupling of p65 from IkBa results
can be explained by the existence of other forms of IkB( I kBb,
IkBc,I kBe) that are subjected to regulation different from that of
IkBa [32]. These variants of IkB could avoid regulation exerted by
LY379268, thus holding their diminished levels and allowing p65
to remain at the nucleus, even after cytosolic levels of IkBa have
been restored. In fact, the association of IkBb with sustained
activity of NF-kB over time has been described, since the
resynthesis rate of IkBb is slower than that of IkBa [33].
Moreover, other authors also reported similar uncoupling of NF-
kB from IkB activity [34].
As we mentioned above, an anti-apoptotic role for p65-c-Rel
heterodimers has been proposed [24,35–37], since their nuclear
activity leads to transcription of Bcl-2 and Bcl-xL genes. Based on
this background, we suggest that NO-inhibited and mGluR3
agonists-induced p65-c-Rel nuclear levels in astrocytes might
support a protective role of these heterodimers and could be
correlated with the modulation of Bcl-2 family proteins previously
reported [3]. We also observed that the effect of mGluR3 agonists
is specific for p65-c-Rel interaction, given that they did not modify
free p65 nuclear levels. Since we found no synergic effect of
LY379268 and LPS/IFN-c on p65-c-Rel interaction, it is likely
that both stimuli are converging at the same signaling pathway.
This pathway could be PI3K/Akt, which is known to be induced
by both agents [8,38], tallying with our present data which show
that both LPS/IFN-c and the mGluR3 agonist activate Akt.
Figure 5. Cytoprotective action of mGluR3 agonists is mediat-
ed by reduction of cAMP levels but not by cGMP. Astrocyte
primary cultures were incubated with 1 mM DETA/NO in the presence
or absence of 100 mM LY379268 and/or 1 mM db-cAMP or 1 mM 8Br-
cGMP for 48 h. Cell viability was assayed by the MTT method. Bars
represent the mean 6 SEM of 6–8 determinations per group, of one
representative experiment of 2 independent ones. *p,0.05 versus
control; ‘p,0.05 versus DETA/NO; ###p,0.001 versus DETA/
NO+LY379268.
doi:10.1371/journal.pone.0022235.g005
Figure 6. Akt activity mediates the antiapoptotic effect of
mGluR3 agonists in astrocytes. (A) A dose-response curve was
plotted by a MTT assay to determine the optimal concentration of the
Akt inhibitor. (B) Astrocytes were treated with 1 mM DETA/NO in the
presence or absence of 100 mM LY404039 and/or Akt inhibitor (0.5 mM)
for 48 h. Cell viability was assayed by the MTT method. Bars represent
the mean 6 SEM of 6–8 determinations per group of one
representative experiment of 2 independent ones. **p,0.01 versus
control; ‘‘‘p,0.001 versus DETA/NO; ###p,0.001 versus DETA/
NO+LY404039.
doi:10.1371/journal.pone.0022235.g006
Figure 4. mGluR3 activation avoids inhibition of p65-c-Rel
dimerization provoked by DETA/NO. p65-c-Rel interaction was
analyzed by co-immunoprecipitation (IP) followed by western-blot (WB)
of nuclear extracts from astrocytes treated with 1 mM DETA/
NO6100 mM LY404039 for 30 min. Levels of anti-c-Rel-immunoprecip-
itated p65 were expressed relative to control group. Bars represent the
mean 6 SEM of 3 independent experiments. *p,0.05 versus control,
‘p,0.05 versus DETA/NO. Input corresponds to total content of p65 in
nuclear extracts.
doi:10.1371/journal.pone.0022235.g004
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reduction in cAMP levels are required for mGluR3 cytoprotection.
Although the cytotoxicity of cAMP is controversial, some studies
support the hypothesis that a reduction in cAMP levels is a
protective mechanism in the CNS. Faden et al. (1997) reported that
group III mGluR agonists (which also inhibit adenylyl cyclase)
reduce neuronal death induced by mechanical damage and that
this effect is mediated by cAMP inhibition [39]. In fact, cAMP-
induced PKA activity can promote apoptosis [40]. cAMP also
limits membrane localization of phosphoinositide-dependent
Figure 7. LY404039 avoids reduction in phospho-Akt levels
caused by DETA/NO. Total cellular proteins were extracted as
described in Materials and Methods from astrocytes exposed to 1 mM
DETA/NO6100 mM LY40403961 mM db-cAMP for 30 min, and 50 mgo f
protein extracts were assayed for phospho-Akt by western-blot. (A)
Specificity of the western-blot was analyzed by incubating astrocytes
with the PI3K/Akt pathway inhibitor, 20 mM LY294002, which com-
pletely prevented LY404039-induced Akt phosphorylation, and LPS/IFN-
c was used as positive control of Akt activation. Membranes were
stripped and incubated with anti-total Akt antibody, which was
considered loading control. (B) Data were expressed as phospho-Akt/
total Akt ratio and related to control group. Bars represent the mean 6
SEM of 4 independent experiments. *p,0.05, ***p,0.001 versus
control, ‘‘p,0.01 versus LY404039.
doi:10.1371/journal.pone.0022235.g007
Table 1. Akt activity and cAMP reduction mediate the protective effect of mGluR3 on DNA fragmentation induced by NO.
CONTROL DETA/NO DETA/NO+LY404039
DETA/NO+LY404039+Akt
inhibitor DETA/NO+LY404039+db-cAMP
Percentage
of TUNEL positive
cells 6 SEM
2.4461.067 6.2861.207 4.8760.623 6.0161.746 6.8961.395
DNA fragmentation was determined by TUNEL technique, as described in Materials and Methods. Values correspond to the mean 6 SEM of the percentage of TUNEL-
positive astrocytes of 2 independent experiments.
doi:10.1371/journal.pone.0022235.t001
Figure 8. Proposed model for mGluR3 protective actions in
astrocytes. mGluR3 activation by selective ligands couples to Gi
protein activation, which can inhibit adenylyl cyclase activity and cAMP
production and/or directly activate PI3K/Akt pathway. Alternatively,
cAMP reduction could lead to Akt activation, because cAMP inhibits Akt
phosphorylation. In turn, Akt might induce p65-c-Rel interaction at
nucleus, which stimulates the transcription of anti-apoptotic genes
such as Bcl-2, resulting in astrocyte protection from NO challenge.
doi:10.1371/journal.pone.0022235.g008
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these data, we show here that db-cAMP prevents mGluR3-
induced Akt activation and blocks the protective action of
LY379268 on astroglial viability.
Participation of Akt in the survival pathway triggered by
mGluR3 was described earlier in astrocytes deprived of oxygen/
glucose and its activity correlated with Bad inhibition, Bcl-xL
induction [8] and TGF-b release [7]. Akt was shown to
phosphorylate several proapoptotic proteins leading to suppression
of death signals [42]. Our data indicate that NO reduces Akt
activation, which may be one initial event in the triggering of the
apoptotic cascade. Further, since PI3K/Akt activation precedes
NOS up-regulation [38,43,44], NO might inhibit the PI3K/Akt
pathway as part of a negative feedback mechanism. The
restoration of DETA/NO-reduced phospho-Akt levels by
LY404039 correlates with present data indicating that Akt activity
is involved in cytoprotective actions of mGluR3 in astrocytes.
Despite the correlation between astrocyte death induced by
both LPS/IFN-c and NO, and the fact that NO has demonstrated
to be the mediator of LPS/IFN-c-induced cell death [3], signaling
transduction mediators of LPS/IFN-c and NO do not seem to be
exactly the same ones. In fact, we have shown in the present work
that, while LPS/IFN-c induces Akt and NF-kB activation, NO
inhibits both Akt phosphorylation and p65-c-Rel interaction.
Although these inhibitory effects are coherent with the NO pro-
apoptotic role, LPS/IFN-c can also induce astrocyte death by
activating a broad range of alternative pathways such as p38
MAPK and JNK [45–47], in spite of its effects on Akt and p65-c-
Rel. Finally, LPS/IFN-c stimulus is able to induce astrocyte death
through NO production, although (possibly because of the side
activation of Akt and p65-c-Rel) the quantity of dead astrocytes by
LPS/IFN-c is lower than that induced by NO [3]. This evidence
indicates that mGluR3 activation would prevent LPS/IFN-c-
induced astrocyte death by reducing NO synthesis, whereas it
could block NO-induced astrocyte death by keeping Akt and p65-
c-Rel levels up.
In agreement with other authors [41,48], our present results
show that cAMP can inhibit Akt phosphorylation, and thus
mGluR3-reduced cAMP levels could lead to Akt pathway
activation. Since Akt was also reported to promote NF-kB activity
[38,44,49], we propose that Akt activity might induce nuclear p65-
c-Rel interaction, directing the synthesis of anti-apoptotic
members of the Bcl-2 family and ultimately modulating the cell
death cascade induced by NO in astrocytes (Fig. 8).
In summary, we identified novel aspects of the signal
transduction system associated with mGluR3 activation in
astrocytes, which may be responsible for the cytoprotective actions
of mGluR3 agonists in NO-exposed astrocytes. Elucidation of the
mechanisms activated by mGluR3 agonists may offer insights for
potential future therapeutic strategies for the treatment of
neurodegenerative disorders associated with high NO production
and astrocyte loss.
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